5.36
0.28 (5.51%)
| Previous Close | 5.08 |
| Open | 5.10 |
| Volume | 569,661 |
| Avg. Volume (3M) | 703,016 |
| Market Cap | 368,490,496 |
| Price / Book | 2.84 |
| 52 Weeks Range | |
| Earnings Date | 12 Nov 2025 |
| Diluted EPS (TTM) | -3.14 |
| Total Debt/Equity (MRQ) | 19.91% |
| Current Ratio (MRQ) | 4.95 |
| Operating Cash Flow (TTM) | -82.77 M |
| Levered Free Cash Flow (TTM) | -46.26 M |
| Return on Assets (TTM) | -40.84% |
| Return on Equity (TTM) | -75.45% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | PepGen Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 1.0 |
| Insider Activity | 3.0 |
| Price Volatility | -4.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -0.5 |
| Average | -0.20 |
|
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle and the central nervous system. Its pipeline products are; PGN-EDO51, PGN-EDODM1, and others including PGN-EDO53 and PGN-EDO45. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 0.27% |
| % Held by Institutions | 95.95% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 15.00 (Oppenheimer, 179.85%) | Buy |
| Median | 11.00 (105.22%) | |
| Low | 7.00 (Guggenheim, 30.60%) | Buy |
| Average | 11.00 (105.22%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 6.47 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Oppenheimer | 25 Feb 2026 | 15.00 (179.85%) | Buy | 6.40 |
| Guggenheim | 18 Feb 2026 | 7.00 (30.60%) | Buy | 6.54 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| DONNELLY NOEL | 6.22 | - | 76,793 | 477,652 |
| KASRAIAN KASRA | 6.22 | - | 34,557 | 214,945 |
| MCARTHUR JAMES G | 6.22 | - | 187,688 | 1,167,419 |
| STRECK PAUL | 6.22 | - | 50,300 | 312,866 |
| VITTIGLIO JOSEPH | 6.22 | - | 30,717 | 191,060 |
| Aggregate Net Quantity | 380,055 | |||
| Aggregate Net Value ($) | 2,363,942 | |||
| Aggregate Avg. Buy ($) | 6.22 | |||
| Aggregate Avg. Sell ($) | - | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| MCARTHUR JAMES G | Officer | 01 Mar 2026 | Acquired (+) | 187,688 | 6.22 | 1,167,419 |
| DONNELLY NOEL | Officer | 01 Mar 2026 | Acquired (+) | 76,793 | 6.22 | 477,652 |
| STRECK PAUL | Officer | 01 Mar 2026 | Acquired (+) | 50,300 | 6.22 | 312,866 |
| KASRAIAN KASRA | Officer | 01 Mar 2026 | Acquired (+) | 34,557 | 6.22 | 214,945 |
| VITTIGLIO JOSEPH | Officer | 01 Mar 2026 | Acquired (+) | 30,717 | 6.22 | 191,060 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |